Genetic Inhibition of PCSK9 and Liver Function

Antoine Rimbert; Sarra Smati; Wieneke Dijk; Cédric Le May; Bertrand Cariou

doi:10.1001/jamacardio.2020.5341

Genetic Inhibition of PCSK9 and Liver Function

JAMA Cardiol. 2021 Mar 1;6(3):353-354. doi: 10.1001/jamacardio.2020.5341.

Authors

Antoine Rimbert¹, Sarra Smati¹, Wieneke Dijk¹, Cédric Le May¹, Bertrand Cariou¹

Affiliation

¹ L'institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France.

Abstract

This study investigates associations of the lifelong genetic inhibition of PCSK9 with plasma liver enzymes and nonalcoholic fatty liver disease by using the loss-of-function variant PCSK9-p.Arg46Leu as a genetic instrument.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alanine Transaminase / blood
Aspartate Aminotransferases / blood
Genetic Association Studies
Humans
Loss of Function Mutation
Non-alcoholic Fatty Liver Disease
PCSK9 Inhibitors*
Proprotein Convertase 9 / genetics*
gamma-Glutamyltransferase / blood

Substances

PCSK9 Inhibitors
gamma-Glutamyltransferase
Aspartate Aminotransferases
Alanine Transaminase
PCSK9 protein, human
Proprotein Convertase 9